Charles A. Kunos

Charles A. Kunos

Auto-generated profile, based on publicly available information

Charles A. Kunos

Sylvester Comprehensive Cancer Center 3 University of Miami Miami, Florida

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
CKCharles A. Kunos
Charles A. Kunos
DFDenise Fabian
Denise Fabian
DNDana Napier
Dana Napier
MSMark S. Stonecypher
Mark S. Stonecypher
RDRavyn M. Duncan
Ravyn M. Duncan
JHJason Hurt
Jason Hurt
Introduction: 212Pb-DOTAM-GRPR1 is a pharmaceutical radioimmunoconjugate consisiting of an α-particle-emitting radionuclide lead-212 (212Pb), a metal chelator DOTAM (1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane), and a gastrin-releasing peptide receptor (GRPR)-targeted antagonist currently being evaluated as therapy in uterine cervix and other cancer types. Previous studies have revealed that a variable proportion of uterine cervix cancer tumors overexpress the radiopharmaceutical target GRPR when assessed by cell proportion and staining intensity immunoreactive scores (IRS). Tumor response to 212Pb-DOTAM-GRPR1 strongly associates with GRPR overexpression, and therefore, it seems reasonable to assess uterine cervix cancer GRPR immunoreactivity for greater insight into the feasibility of using 212Pb-DOTAM-GRPR1 as a radiopharmaceutical treatment.Methods: We examined a series of 33 uterine cervix cancer paraffin-embedded tumors in order to establish whether this tumor type overexpresses GRPR at an IRS score of 6 or higher, as 212Pb-DOTAM-GRPR1 is currently being evaluated in clinical trials against tumors showing such a level of expression.Results: The results show that five of five (100%) primary adenocarcinomas and 10 of 16 (63%) primary squamous cell tumors overexpress GRPR at an IRS score of 6 or higher.Discussion: The frequency of overexpression in this study suggests that 212Pb-DOTAM-GRPR1 radiopharmaceutical treatment may be useful in the management of persistent, recurrent, or metastatic uterine cervix cancer patients. A phase I clinical trial involving patients with metastatic uterine cervix cancer is currently underway (NCT05283330).

9 December 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
CKCharles A. Kunos
Charles A. Kunos
DFDenise Fabian
Denise Fabian
MKMahesh Kudrimoti
Mahesh Kudrimoti
RMRachel W. Miller
Rachel W. Miller
FUFrederick R. Ueland
Frederick R. Ueland
MRMarcus E. Randall
Marcus E. Randall
Uterine cervix cancer (UCCx) is clinically and socioeconomically diverse among women in the United States (US), which obscures the discovery of effective radiochemotherapy approaches for this disease. UCCx afflicts 7.5 per 100,000 American women nationally but 11.7 per 100,000 women in Appalachian Kentucky (AppKY), when age-adjusted to the 2000 US standard population. Epidemiological chart review was performed on 212 women with UCCx treated at the University of Kentucky (UKY) between January 2001 and July 2021. Demographics, tumor characteristics, and relative radiochemotherapy dose and schedule intensity were compared among AppKY and non-AppKY cohorts as well as Surveillance, Epidemiology, and End Results (SEER) data. One hundred thirty-eight (65%) of 212 women seeking radiochemotherapy treatment for UCCx resided in AppKY. Most (80%) sought external-beam radiochemotherapy close to their AppKY residence. Brachytherapy was then most frequently (96%) conducted at UKY. Cancer stage at diagnosis was significantly more advanced in AppKY residents. Women residing in AppKY had a median 10-week radiochemotherapy course, longer than an 8-week guideline. Estimated survival in women residing in AppKY was 8% lower than US national averages. In summary, this study identified an increased percentage of advanced-stage UCCx cancer at diagnosis arising in AppKY residents, with a confounding population-specific delay in radiochemotherapy schedule intensity lowering survival.

6 July 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
CKCharles A. Kunos
Charles A. Kunos
DFDenise Fabian
Denise Fabian
TFTricia Fredericks
Tricia Fredericks
LBLauren Baldwin
Lauren Baldwin
CDCharles Dietrich
Charles Dietrich
FUFrederick R. Ueland
Frederick R. Ueland
Introduction: The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy.Methods: Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control.Results: Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables.Discussion: In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.

24 January 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
CKCharles A. Kunos
Charles A. Kunos
DFDenise Fabian
Denise Fabian
DPDava W. Piecoro
Dava W. Piecoro
DNDana Napier
Dana Napier
RMRachel W. Miller
Rachel W. Miller
FUFrederick R. Ueland
Frederick R. Ueland
Introduction: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide.Methods: We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial.Results: Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so.Discussion: Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted.

27 June 2023 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
CKCharles A. Kunos
Charles A. Kunos
RPRichard Piekarz
Richard Piekarz
JCJerry M. Collins
Jerry M. Collins
TKTimothy J. Kinsella
Timothy J. Kinsella
Background: Rectal carcinomas are tumors that arise from the last 12 cm of the large intestine closest to the anus. They generally have a modest prognosis exacerbated by a high local recurrence rate if radiosensitizing chemotherapy is not given during radiotherapy. This case report discusses the clinical trial treatment of a patient with rectal adenocarcinoma by a new ropidoxuridine–capecitabine–radiotherapy combination. This case report is novel due to the patient’s participation in an accelerated titration phase I clinical trial and the resultant rare adverse event of treatment-related sigmoid typhlitis. Case presentation: The patient was an 82-year-old female who noticed hematochezia and change in stool caliber over a period of 3 months. A rectal mass was identified by biopsy as a microsatellite stable adenocarcinoma. A planned total neoadjuvant treatment involved eight cycles of leucovorin calcium (folinic acid)–fluorouracil–oxaliplatin (mFOLFOX6) chemotherapy, followed by a clinical trial combination of ropidoxuridine–capecitabine–radiotherapy, prior to definitive surgery. The patient began daily intensity modulated pelvic radiotherapy with concurrent twice-daily oral ropidoxuridine and twice-daily oral capecitabine to be given over 6 weeks. After 14 days of ropidoxuridine–capecitabine–radiotherapy, the patient developed sigmoid typhlitis requiring a 10-day hospitalization and 14-day disruption of treatment. The patient died 27 days after the start of ropidoxuridine–capecitabine–radiotherapy. This adverse event was listed as a definite attribution to the ropidoxuridine–capecitabine treatment; pharmacokinetic and pharmacodynamic data showed low ropidoxuridine metabolite DNA incorporation and high capecitabine metabolite concentration. The accelerated titration phase I clinical trial has been subsequently closed to accrual (NCT04406857). Conclusions: We believe this case report demonstrates the decision-making process for terminating a phase I accelerated titration designed clinical trial. The report also presents the rare complication of sigmoid typhlitis as a treatment-attributed adverse event. In this case, a ropidoxuridine–capecitabine combination was used as an investigational radiosensitizing treatment now with a narrower future clinical development pathway.

28 July 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
ACAman Chauhan
Aman Chauhan
HWHeidi L. Weiss
Heidi L. Weiss
CKCharles Kunos
Charles Kunos
RJRani Jayswal
Rani Jayswal
BKBhavana Konda
Bhavana Konda
SASusanne M Arnold
Susanne M Arnold
Purpose: The next generation of theranostics studies is looking at novel combinations with radiation sensitizers to enhance peptide receptor radionuclide therapy’s efficacy. In this study, we present safety and efficacy data from a multicenter phase I study of a [177Lu]lutetium-dotatate–triapine combination in patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET). Patients and Methods: The study consisted of 2 phases (part A: dose escalation; part B: dose expansion) administering the recommended phase II doses (RP2D) for the 2 agents. All patients received 200 mCi of [177Lu]lutetium-dotatate on day 1 of four 8-week cycles, in combination with oral triapine administered at assigned dose levels (100, 150, or 200 mg) from day 1 to day 14 of each cycle. Results: A total of 31 (A: 15; B: 16) patients received treatment. Across the study, 9 patients experienced dose-limiting toxicities: grade 3 anemia (n = 1), grade 5 cardiac arrest (unrelated to investigational product; n = 1), and grade 4 neutropenia (n = 7). Based on the overall safety and pharmacokinetics data, a [177Lu]lutetium-dotatate (200 mCi) plus triapine (150 mg) dose was selected as the RP2D for the expansion phase. Grade ≥3 treatment-related adverse events were observed in 77% of patients: anemia (23%), nausea and vomiting (3%), lymphopenia (58%), neutropenia (35%), and decreased white blood cell count (39%). The majority of cytopenias were transient and resolved within 2 weeks. Among the 28 evaluable patients, the objective response rate was 21.4%, and the median progression-free survival has not been reached (median follow-up period, 23.7 months). Conclusions: The combination of [177Lu]lutetium-dotatate (200 mCi) and oral triapine (150 mg D1-14) was well tolerated and demonstrated preliminary activity in patients with well-differentiated GEP-NET (NCT04234568).